These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 9064945)

  • 1. [Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
    Mitrovic V; Mudra H; Bonzel T; Schmidt W; Schlepper M
    Z Kardiol; 1996 Nov; 85(11):828-38. PubMed ID: 9064945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure.
    Mitrovic V; Mudra H; Bonzel T; Schmidt W; Strand JC; Bakovic-Alt R; Posvar EL
    Clin Pharmacol Ther; 1996 Jun; 59(6):686-98. PubMed ID: 8681494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
    Sedman AJ; Posvar E
    Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
    Breslin E; Posvar E; Neub M; Trenk D; Jahnchen E
    J Clin Pharmacol; 1996 May; 36(5):414-21. PubMed ID: 8739020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany.
    Nussberger J; Fleck E; Bahrmann H; Delius W; Schultheiss HP; Brunner HR
    Eur Heart J; 1994 Dec; 15 Suppl D():113-22. PubMed ID: 7713100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure.
    Squire IB; Macfadyen RJ; Lees KR; Hillis WS; Reid JL
    Br J Clin Pharmacol; 1994 Aug; 38(2):117-23. PubMed ID: 7981011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
    Davis JL; Kruger K; LaFevers DH; Barlow BM; Schirmer JM; Breuhaus BA
    Equine Vet J; 2014 Nov; 46(6):729-33. PubMed ID: 24175935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model.
    Whelton A; McCormick L; Wombolt D; Goldstein R; Canter D
    Eur Heart J; 1997 Jan; 18(1):140-7. PubMed ID: 9049526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conversion from oral ACE inhibitor to intravenous quinaprilat administration in mild to moderate essential hypertension].
    Schmidt BM; Smilde J; Oldenbroek C; Wehling M
    Med Klin (Munich); 1998 Dec; 93(12):701-6. PubMed ID: 10024837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose enoximone therapy in pre-transplant patients: hemodynamic, echocardiographic, and neurohumoral findings.
    Park JW; Heinzler R; Wirtz JH; Fieten-Rumswinkel M; Braun P; May E; Hetzer R; Heinrich KW
    Z Kardiol; 1994; 83 Suppl 2():49-53. PubMed ID: 8091824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
    Davidson NC; Coutie WJ; Webb DJ; Struthers AD
    Heart; 1996 Jun; 75(6):576-81. PubMed ID: 8697160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure.
    Dickstein K
    J Cardiovasc Pharmacol; 1987; 9 Suppl 3():S73-81. PubMed ID: 2442558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure.
    Evans MA; Burnett JC; Redfield MM
    J Am Coll Cardiol; 1995 May; 25(6):1445-50. PubMed ID: 7722147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
    Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
    Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.
    Begg EJ; Robson RA; Bailey RR; Lynn KL; Frank GJ; Olson SC
    Br J Clin Pharmacol; 1990 Aug; 30(2):213-20. PubMed ID: 2144994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
    Tang WH; Vagelos RH; Yee YG; Fowler MB
    Am Heart J; 2004 Nov; 148(5):889-94. PubMed ID: 15523323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.